

DLA PIPER RUDNICK GRAY CARY US LLP

1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

ifw

DOCKET NO.: 3802-068-27 CIP

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Re: Serial No.: 10/743,813
Applicant(s): Nagarajan RAMESH, et al.
Filing Date: December 24, 2003
For: METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS
TRANSDUCTION IN THE BLADDER EPITHELIUM
Group Art Unit: 1614
Examiner:

SIR:


Attached hereto for filing are the following papers:

Information Disclosure Statement
International Search Report
Form PTO-1449
Cited Documents (12)

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DLA PIPER RUDNICK GRAY CARY US LLP



Linda R. Judge
Registration No.: 42,702

IN RE APPLICATION: Nagarajan RAMESH, et al

GROUP ART UNIT: 1614

SERIAL NUMBER: 10/743,813

EXAMINER:

FILED: December 24, 2003

FOR: METHODS AND REAGENTS FOR THE ENHANCEMENT OF VIRUS TRANSDUCTION IN THE BLADDER EPITHELIUM

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
PO BOX 1450
ALEXANDRIA, VA 22313-1450

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached International Search Report and Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents.

RELATED CASES

- Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:


- without fee and within three months of the filing date of the application.
- without fee and within three months of the date of entry of the U.S. national stage.
- without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- without fee and with the appropriate certification above.
- without fee and with a new CPA application.
- without fee and with a Request for Continued Examination.
- with fee and before the mailing date of any Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,

DLA PIPER RUDNICK GRAY CARY US LLP


Linda R. Judge
Registration No. 42,702

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 3802-068-27 CIP		SERIAL NO. 10/743,813	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Nagarajan RAMESH, et al.					
		FILING DATE December 24, 2003				GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AB	WO 02/40630	05/23/02	WIPO	X		
	AC	JP 1-245159	09/29/89	JAPAN		X	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AD	Mizamura, et al., "Plates for detection of antibodies to Newcastle disease virus and octyl-glucoside solubilization of virus antigen", Database CAPLUS on STN, No. 1990:115384, Abstract Only, 1990.					
	AE	Zhang, et al., "Identification of Human Uroplakin II Promoter and Its Use in the Construction of CG8840, a Urothelium-specific Adenovirus Variant That Eliminates Established Bladder Tumors in Combination with Docetaxel", Cancer Research, Vol. 62, pp. 3743-3750, 2002.					
	AF	Connor, et al., "Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium", Gene Therapy, Vol. 8, pp. 41-48, 2001.					
	AG	Watanabe, et al., "Adenovirus-Mediated Gene Therapy for Bladder Cancer in an Orthotopic Model Using a Dominant Negative H-RAS Mutant", Int. J. Cancer, Vol. 92, pp. 712-717, 2001.					
	AH	Mullen, et al., "Viral Oncolysis", The Oncologist, Vol. 7, pp. 106-119, 2002.					
	AI	Boer, et al., "Solubilization of Ligand-Stabilized Vasopressin Receptors from Plasma Membranes of Bovine Kidney and Rat Liver", Biochem. Biophys. Res. Comm., Vol. 116, No. 1, pp. 91-98, 1983.					
	AJ	Sedzik, et al., "Solubilization of PNS myelin membrane proteins by detergents", Membrane Biophysics and Biochemistry, Vol. 11, No. 11, pp. 2559-2563, 2000.					
	AK	Kim, "Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer", Oncogene, Vol. 19, pp. 6660-6669, 2000.					
	AL	Rangel, et al., "Taxol and taxotere in bladder cancer: in vitro activity and urine stability", Cancer Chemother. Pharmacol., Vol. 33, pp. 460-464, 1994.					
	AM	Loughlin, et al., "The Use of Hydrogen Peroxide to Enhance the Efficacy of Doxorubicin Hydrochloride in a Murine Bladder Tumor Cell Line", H. Urology, Vol. 165, pp. 1300-1304, 2001.					
EXAMINER					DATE CONSIDERED		
*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							